Clinical Trials Logo

Metabolism, Inborn Errors clinical trials

View clinical trials related to Metabolism, Inborn Errors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05425745 Active, not recruiting - Clinical trials for Hypercholesterolemia

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

BROOKLYN
Start date: July 25, 2022
Phase: Phase 3
Study type: Interventional

This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia (HeFH).

NCT ID: NCT03548779 Active, not recruiting - Clinical trials for Autism Spectrum Disorder

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2

NCGENES2
Start date: September 28, 2018
Phase: N/A
Study type: Interventional

The "North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family well-being as well as diagnostic efficacy, management planning, and medical outcomes. A clinical trial will be implemented to compare (1) first-line exome sequencing to usual care and (2) participant pre-visit preparation to no pre-visit preparation. The study will use a randomized controlled design, with 2x2 factorial design, coupled with patient-reported outcomes and comprehensive clinical data collection addressing key outcomes, to determine the net impact of diagnostic results and secondary findings.

NCT ID: NCT02635269 Active, not recruiting - Clinical trials for Glycogen Storage Disease Type II

Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy

Start date: January 2016
Phase: N/A
Study type: Interventional

This study aims to characterize the pathophysiological mechanisms of 21 different metabolic myopathies. The study will focus on exercise capacity and the metabolic derangement during exercise.

NCT ID: NCT00843921 Active, not recruiting - Clinical trials for Inborn Errors of Metabolism

N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia

Start date: August 2008
Phase: Phase 2/Phase 3
Study type: Interventional

This study is based on the hypothesis that a new drug N-carbamylglutamate (Carbaglu®) will enhance the ability of the liver to dispose of toxic ammonia which accumulates in several metabolic diseases including urea cycle disorders and organic acid disorders.